AXIM BIOTECHNOLOGIES, INC. — Earnings
Most recent reported period: FY2024 (Q2) (filed for period ending 2024-06-30) · sourced from SEC EDGAR
Next earnings (estimated): Sun, September 29, 2024 — 579 days overdue (likely already filed but EDGAR cache cold). Anchored to latest quarter-end + 91 days. Analyst-confirmed dates land in a follow-up wave.
YoY = vs same quarter prior year (seasonality-adjusted)
Recent earnings · last 8 quarters
| Quarter end | Revenue | YoY | Net Income | YoY | Op. Margin |
|---|---|---|---|---|---|
| 2024-06-30 | $17K | ↑+76.0% | $-2M | ↑+39.0% | -3257.9% |
| 2024-03-31 | $53K | ↑+616.2% | $-292K | ↑+89.4% | -758.0% |
| 2023-12-31 | $13K | ↑+70.1% | — | — | — |
| 2023-09-30 | $10K | ↑+629.1% | $328K | ↑+116.1% | -6142.7% |
| 2023-06-30 | $10K | — | $-4M | ↓-204.5% | -7027.2% |
| 2023-03-31 | $7K | — | $-3M | ↓-32.4% | -9607.1% |
| 2022-12-31 | $8K | ↑+57.2% | $2M | ↓-91.7% | — |
| 2022-09-30 | $1K | ↓-83.8% | $-2M | ↑+38.2% | -100298.3% |
Analyst consensus estimates (EPS / Revenue) and implied move from options will land in a follow-up wave. For now, YoY-vs-prior-year-quarter is the surprise proxy.
Last earnings · FY2024 (Q2)
Revenue
$17K
↑+76.0% +$8K YoY
Earnings surprise · last 8 quarters
YoY % change · proxy for analyst surprise until estimates landEPS history · last 10 fiscal years
diluted, GAAP, annualNote: EPS reflects WEIGHTED-AVERAGE diluted shares for each fiscal year. Pre-stock- split values can blow up the early bars if SEC's XBRL data isn't split-adjusted — flagged as a known limitation; cumulative split-adjustment is a follow-up.
Margin trends · 52 quarters
margin trajectory tells the operating-leverage storyGross Margin↓-10.0pts
90.0%
Operating Margin↑+3769.3pts
-3257.9%
Net Margin↑+24513.2pts
-12986.0%
Go deeper
AXIM Sankey — flow of dollars
See how revenue waterfalls through every line item to net income for the latest reported quarter, with prior-period comparison.
Open SankeyAXIM Key Metrics — EPS, ROE, ROIC
10 CFA-grade fundamental ratios — EPS, BVPS, ROE, ROA, ROIC, Debt/Equity, Current Ratio. Compare across years.
Open Key Metrics